Psoriasis is often associated with an overproduction of C-reactive protein (CRP). Patients at increased risk for cardiovascular disease (CVD) also frequently have elevated CRP levels. This article reviews the latest data on the connection between CRP, CVD, and psoriasis. Patients with elevated CRP levels as well as those with psoriasis may be at increased risk for CVD, yet some controversy exists over the strength of these correlations. Several systemic treatments for psoriasis have CRP-lowering effects, although a connection between reductions in CRP levels and clinical clearance of psoriatic disease has not been studied extensively. Limited data are available on the relationship between psoriasis severity and CRP. While the articles included in this review begin to uncover the relationship between CRP and psoriasis, they also illustrate several confounding variables and an incomplete understanding of CRP's clinical application in psoriasis. A large-scale, detailed psoriasis patient database would provide a more accurate assessment of the association between CRP, CVD, and psoriasis.
ZhangD., JiangS.L., RzewnickiD., SamolsD., KushnerI.The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level. Biochem J.1995; 310(1) 143–8.
3.
ReillyM.P., RohatgiA., McMahonK.Plasma cytokines, metabolic syndrome, and atherosclerosis in humans. J Investig Med2007; 55(1): 26–35.
4.
PasceriV., WillersonJ.T., YehE.T.Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation2000; 102(18): 2165–8.
5.
VenugopalS.K., DevarajS., YuhannaI., ShaulP., JialalI.Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation.2002; 106(12): 1439–41.
6.
ZwakaT.P., HombachV., TorzewskiJ.C-reactive protein mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation.2001; 103(9) 1194–7.
7.
VermaS., WangC.H., LiS.H.A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation.2002; 106(8): 913–9.
8.
DanenbergH.D., SzalaiA.J., SwaminathanR.V.Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation.2003; 108(5): 512–5.
9.
DevarajS., XuD.Y., JialalI.C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation.2003; 107(3); 398–404.
10.
BallouS.P., LozanskiG.Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine1992; 4(5): 361–8.
11.
de FerrantiS.D., RifaiN.C-reactive protein: a nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol.2007; 16(1) 14–21.
12.
GottliebA.B., DannF., MenterA.Psoriasis and the metabolic syndromeJ Drugs Dermatol.20087(6): 563–72.
13.
KushnerI., SamolsD., MagreyM.A unifying biologic explanation for “high-sensitivity” C-reactive protein and “low-grade” inflammation. Arthritis Care Res.2010; 62(4): 442–6.
14.
HotamisligilG.S.Inflammation and metabolic disorders. Nature2006; 444(7121): 860–7.
15.
LuJ.H., TehB.K., WangL.The classical and regulatory functions of C1q in immunity and autoimmunity. Cell Mol Immunol.2008; 5(1): 9–21.
16.
SjöbergA.P., TrouwL.A., McGrathF.D., HackC.E., BlomA.M.Regulation of complement activation by C-reactive protein: targeting of the inhibitory activity of C4b-binding protein. J Immunol.2006; 176(12) 7612–20.
17.
CaseyR., NewcombeJ., McFaddenJ., Bodman-SmithK.B.The acute-phase reactant C-reactive protein binds to phosphorylcholine-expressing Neisseria meningitidis and increases uptake by human phagocytes. Infect Immun.2008; 76(3): 1298–304.
18.
MenterA., GottliebA., FeldmanS.R.Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol.2008; 58(5): 826–50.
19.
DayerE., DayerJ.M., Roux-LombardP.Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseasesNat Clin Pract Rheumatol.2007; 3 (9): 512–20.
20.
JohnsonH.L., ChiouC.C., ChoC.T.Applications of acute phase reactants in infectious diseases. J Microbiol Immunol Infect.1999; 32(2) 73–82.
21.
RidkerP.M.High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation.2001; 103(13) 1813–8.
22.
Meier-EwartH.K., RidkerP.M., RifaiN., PriceN., DingesD.F., MullingtonJ.M.Absence of diurnal variation of C-reactive protein levels in healthy human subjects. Clin Chem.2001; 47(3): 426–30.
23.
OckeneI.S., MatthewsC.E., RifaiN., RidkerP.M., ReedG., StanekE.Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem2001; 47(3): 444–50.
24.
SesmiloG., BillerB.M., LlevadotJ.Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: a randomized, controlled clinical trial. Ann Intern Med.2000; 133(2) 111–22.
25.
van BaalW.M., KenemansP., van der MoorenM.J., KesselH., EmeisJ.J., StehouwerC.D.Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal womenThromb Haemost.1999; 81(6): 925–8.
26.
RidkerP.M., HennekensC.H., RifaiN., BuringJ.E., MansonJ.E.Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation.1999; 100(7)713–6.
27.
CushmanM., LegaultC., Barrett-ConnorE.Effect of postmenopausal hormones on inflammation-sensitive proteins the postmenopausal estrogen/progestin interventions (PEPI) studyCirculation.1999; 100(7) 717–22.
28.
VisserM., BouterL.M., McQuillanG.M., WenerM.H., HarrisT.B.Elevated C-reactive protein levels in overweight and obese adults. JAMA.1999; 282(22): 2131–5.
29.
FestaA., D'AgostinoR.Jr., HowardG., MykkänenL., TracyR.P., HaffnerS.M.Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)Circulation.2000; 102(1): 42–7.
30.
HerronM.D., HinckleyM., HoffmanM.S.Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol2005; 141(12): 1527–34.
31.
WoloshinS., SchwartzL.M.Distribution of C-reactive protein values in the United States. N Engl J Med.2005; 352(15): 1611–3.
32.
ZachoJ., Tybjærg-HansenA., JensenJ.S., GrandeP., SillesenH., NordestgaardB.G.Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med.2008; 359(18): 1897–908.
33.
RidkerP.M.C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol.2007; 49(21): 2129–38.
34.
DaneshJ., WheelerJ.G., HirschfieldG.M.C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med.2004; 350(14): 1387–97.
35.
van der MeerI.M., de MaatM.P., KiliaanA.J., van der KulpD.A., HofmanA, WittemanJ.C.The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam study. Arch Intern Med.2003; 163(11): 1323–8.
36.
KoenigW., LöwelH., BaumertJ., MeisingerC.C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation.2004; 109(11): 1349–53.
37.
CurrieC.J., PooleC.D., ConwayP.Evaluation of the association between the first observation and the longitudinal change in C-reactive protein and all-cause mortality. Heart.2008; 94(4): 457–62.
38.
PooleC.D., ConwayP., CurrieC.J.An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology2009; 48(1): 78–82.
39.
GelfandJ.M., TroxelA.B., LewisJ.D.The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol2007; 143(12): 1493–9.
40.
GelfandJ.M., NeimannA.L., ShinD.B., WangX., MargolisD.J., TroxelA.B.Risk of myocardial infarction in patients with psoriasis. JAMA2006; 296(14): 1735–41.
41.
GelfandJ.M., DommaschE.D., ShinD.B.The risk of stroke in patients with psoriasis. J Invest Dermatol.2009; 129(10): 2411–8.
42.
MehtaN.N., AzfarR.S., ShinD.B.Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J.2010; 31(8): 1000–6.
43.
WakkeeM., HeringsR.M.C., NijstenT.Psoriasis may not bean independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol2010; 130(4): 962–7.
44.
BalciD.D., BalciA., KarazincirS.Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol.2009; 23(1): 1–6.
45.
El-MongyS., FathyH., AbdelazizA.Subclinical atherosclerosis in patients with chronic psoriasis: a potential association. J Eur Acad Dermatol Venerol.2010; 24(6): 661–6.
46.
GisondiP., FantinF., Del GiglioM.Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology.2009; 218(2): 110–3.
47.
SternR.S., LangeR.Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol.1988; 91(3): 197–201.
48.
SternR.S., HuibregtseA.Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. J Invest Dermatol.2011 [Epub ahead of print]
49.
AlevizosA., LariosG., MariolisA.Psoriasis and risk of myocardial infarction. JAMA.2007; 297(4): 361.
50.
MalerbaM., GisondiP., RadaeliA., GirolomoniG.Psoriasis and risk of myocardial infarction. JAMA.2007; 297(4): 361–2.
51.
NeimannA.L., ShinD.B., WangX., MargolisD.J., TroxelA.B., GelfandJ.M.Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol.2006; 55(5): 829–35.
52.
TamL.S., TomlinsonB., ChuT.T.Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology.2008; 47(5): 718–23.
53.
OhtsukaT.The correlation between response to oral cyclosporine therapy and systemic inflammation, metabolic abnormality in patients with psoriasis. Arch Dermatol Res.2008; 300(10): 545–50.
54.
StroberB., TellerC., YamauchiP.Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol.2008; 159(2): 322–30.
55.
SerwinA.B., WasowiczW., ChodynickaB.Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrow band ultravioletB Nutrition.2006; 22(9): 860–4.
56.
LeonardiC.L., PowersJ.L., MathesonR.T.Etanercept as monotherapy in patients with psoriasis. N Engl J Med.2003; 349(21): 2014–22.
57.
Rocha-PereiraP., Santos-SilvaA., RebeloI., FigueiredoA., QuintanilhaA., TeixeiraF.The inflammatory response in mild and in severe psoriasisBr J Dermatol.2004; 150(5): 917–28.
58.
SergeantA., MakrygeorgouA., ChanW.C., ThorratA., BurdenD.C-reactive protein in psoriasis. Br J Dermatol.2008; 158(2): 417–9.
59.
BoselloS., SantoliquidoA., ZoliA.TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing rheumatoid arthritis. Clin Rheumatol2008; 27(7): 833–9.
60.
PepysM.B., HirschfieldG.M., TennentG.A.Targeting C-reactive protein for the treatment of cardiovascular disease. Nature2006; 440(7088): 1217–21.
